Clinical Trial Update: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and biomarker signals for DK210, an EGFR-targeting therapy, across multiple EGFR-positive solid tumors; current status is active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gynecologic Cancer
• Head and Neck Cancer
• Kidney Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Skin Cancer

Drugs mentioned

• DK210 (DK210)

Snippet

Sponsor: DEKA Biosciences | Conditions: Cancer, Solid Tumor | Phase 1 | Status: ACTIVE_NOT_RECRUITING